- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04105439
Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Relation Between Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Study Overview
Status
Conditions
Detailed Description
Behçet's disease (BD) is a chronic, systemic vasculitis disease that can be evident in many systems and characterized by recurrent attacks, oral and/or genital aphthous ulcers, skin lesions, and inflammatory ocular findings. It was first described in 1937 by the Turkish dermatologist Hulusi Behçet.[1-3]
Although with an unclear pathogenesis, BD is considered a type of vasculitis triggered by immunological mechanisms. Increased levels of pro-inflammatory cytokines are reported in patients with BD. In the afflicted organs, a remarkable infiltration of neutrophils and lymphocytes can be seen.[4-6]
Diagnosis of BD is mainly clinical, on the association of symptoms, but diagnosis/classification criteria may help. Various sets of criteria were created for BD diagnosis and the recent one is the international criteria for Behçet's disease (ICBD) that was created by 27 countries in 2006 and revised in2014.[7]
There is no standard laboratory marker for the diagnosis and follow-up of BD. certain cytokines and increased serum levels of C-reactive protein (CRP) are considered as markers of disease activity.[8] Soluble urokinase plasminogen activator receptor (suPAR), a potential new biomarker, is a soluble form of the membrane-bound receptors expressed from and comprising mainly of various immune cells (monocytes, neutrophils, activated T lymphocytes, macrophages, endothelial cells, keratinocytes, smooth muscle cells and even tumor cells. [9] Numerous studies on various inflammatory diseases, cancer, tuberculosis, central nervous system infections, sepsis, liver fibrosis and inflammatory bowel disease have shown increased systemic levels of suPAR. In these diseases, suPAR systemic levels are shown to have a prognostic value in determining disease severity.[10]
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Mohamed Farghaly Ramadan, MD
- Phone Number: 01120782662
- Email: el.5abiry@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18
- Patients diagnosed as Behçet's disease according to international study group criteria (ICBD ) for diagnosis of Behçet's
Exclusion Criteria:
- Age< 18 years
- Other autoimmune diseases.
- Pregnancy.
- Acute and chronic systemic infection history.
- The presence of chronic diseases such as chronic renal failure, liver and cardiac failure.
- Presence or history of cancer.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
control
healthy subjects who do not have the disease
|
patients with Behçet's disease
subjects who do have the disease ( Behçet's disease )
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluation of the level of suPAR in the study subjects.
Time Frame: baseline
|
to study the relation between leve of the marker and presence of the diesase.
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluation of the levels of suPAR with the activity of the disease.
Time Frame: baseline
|
to study relation between level of the marker and activity of the disease
|
baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990 May 5;335(8697):1078-80.
- Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S, et al. Vascular involvement in Behcet's disease. J Rheumatol. 1992 Mar;19(3):402-10.
- Kose O. Development of Immunopathogenesis Strategies to Treat Behcet's Disease. Patholog Res Int. 2012;2012:261989. doi: 10.1155/2012/261989. Epub 2012 Apr 3.
- Tursen U. Pathophysiology of the Behcet's Disease. Patholog Res Int. 2012;2012:493015. doi: 10.1155/2012/493015. Epub 2011 Oct 1.
- International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47. doi: 10.1111/jdv.12107. Epub 2013 Feb 26.
- Adam B, Calikoglu E. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behcet's disease. J Eur Acad Dermatol Venereol. 2004 May;18(3):318-20. doi: 10.1111/j.1468-3083.2004.00907.x.
- Gustafsson A, Ljunggren L, Bodelsson M, Berkestedt I. The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis. Biomark Insights. 2012;7:39-44. doi: 10.4137/BMI.S9460. Epub 2012 Apr 10.
- Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3):157-72. doi: 10.3233/DMA-2009-0657.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- suPAR in behcet disease
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Behçet Disease
-
University of CagliariUnknownBehçet Disease | Behcet's Disease AggravatedGreece, Italy, Portugal, Spain, United Arab Emirates
-
Gazi UniversityNot yet recruitingSleep Quality | Behçet Disease
-
Tianjin Hemay Pharmaceutical Co., LtdTerminated
-
Peking Union Medical College HospitalCompletedUveitis | Behçet DiseaseChina
-
Azienda Ospedaliero, Universitaria PisanaNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Gazi UniversityUnknown
-
AmgenRecruitingBehçet DiseaseSpain, United Kingdom, Turkey, France, Greece, Italy, Israel, Switzerland
-
Karamanoğlu Mehmetbey UniversityActive, not recruiting
-
University Hospital, Clermont-FerrandRecruitingBehçet Disease | Microbiota | Physiopathology | Oral MicrobiotaFrance